At #AACR24 this year, I was tasked with presenting an overview of #radiotheranostics including what the immediate future might hold and a framework to approach it.
One natural next step is repurposing existing agents for other cancers.
1/x
Ludwig Stanford's Zinaida Good discussed at #AACR24 exciting research on a type of immunotherapy in a poster titled, "Lineage tracing defines responding CAR T cells in patients with B cell malignancies."
Ludwig Oxford's Joanna Lima presented research at #AACR24 identifying in mice the early cancerous lesions caused by the loss of a pair of genes—Vhl and Prbm1—whose joint inactivation suffices to initiate a type of renal cancer.
Ludwig @[email protected]'s Nicole Traphagen discusses the research she presented at #AACR24 in a poster titled, "Defining androgen receptor function and the effects of PARP inhibition in BRCA1/2-deficient vs. proficient prostate cancer."
Ludwig @[email protected]'s Bogang Wu presented at #AACR24 his research into the systematic identification of biochemical pathways associated with breast cancer cells' sensitivity to antibody-drug conjugates, a still-young but rapidly growing class of cancer therapies.
Ludwig @[email protected]'s Zuen Ren presented his research at #AACR24 in a poster titled, "Multiomics analysis unravels tumor metabolic reprogramming and potential resistance mechanism(s) to curative therapy in triple negative breast cancer."
Ludwig Oxford's Olivia Lombardi presented a poster at #AACR24 titled "Transcriptional programs underpinning reoccurring cancer cell states, plasticity and tumour phylogenies in clear cell kidney cancer" in a session focused on Tumor Evolution at Single Cell Resolution.
Abram Bunya Kamiza, an AACR scholar-in-training award recipient from Johannesburg, South Africa, whose travel to #AACR24 was supported by the Ludwig Institute, discussed his trans-ethnic analysis of newly identified genomic regions linked to cervical cancer.
Ludwig @[email protected]'s Stephanie Dougan spoke at #AACR24 about her lab's preclinical studies showing how drugs known as CDK4/6 inhibitors might be used in combination with checkpoint blockade immunotherapy to augment anti-tumor immunity without causing serious adverse reactions.
Wafik S. El-Deiry, MD PhD FACP
Freddy E Escorcia 
Ludwig Cancer Research